Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Raw Materials for 9 consecutive years, with $13.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Raw Materials fell 39.16% year-over-year to $13.9 million; the trailing twelve-month figure through Jun 2026 stood at $13.9 million (down 39.16% YoY), and the FY2025 full-year result was $14.2 million, down 40.81% from the prior year.
• Raw Materials improved to $13.9 million in Q2 2026 per ALNY's latest filing, from $11.7 million in the prior quarter.
• Across five years, Raw Materials topped out at $26.0 million in Q2 2024 and bottomed at $11.7 million in Q1 2026.
• Historically, Raw Materials has averaged $20.5 million across 5 years, with a median of $22.3 million in 2022.
• The widest YoY moves for Raw Materials: up 51.25% in 2022, down 72.81% in 2022.
• Over 5 years, Raw Materials stood at $22.3 million in 2022, then advanced by 4.62% to $23.3 million in 2023, then gained by 2.65% to $24.0 million in 2024, then tumbled by 40.81% to $14.2 million in 2025, then fell by 1.91% to $13.9 million in 2026.
• According to Business Quant data, Raw Materials over the past three periods registered $13.9 million, $11.7 million, and $14.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.